anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
86 Patients with lumbar disc prolapse diagnosed by either MRI or CT will be included. All of them aged \> 18 years with no special condition for the duration of disc prolapse. All of them had clinical manifestations in the form of mechanical low back pain or sciatica or limited spine mobility. All participants had no or poor response to conservative treatment. Previous surgery, severe facet arthropathy, ankylosing spondylitis, sensory or motor deficit and wedge fracture were considered as exclusion criteria. Distraction, compression, thigh thrust, and sacral thrust were used to assess SIJ dysfunction only at baseline before injection. Fingertip to floor and Oswestry disability index (ODI) were used to assess mobility and function of the spine at baseline (before and after injection) and after 2 and 16 weeks. Visual Analogue Scale (VAS) was used for pain appraisal at the same intervals. Participants will be randomly assigned into active and control group using 1:1 allocation. In the active group bilateral SIJ injection will be performed under ultrasound US guidance. Under US guidance a 22G spinal needle, where 1 mL 2 % lidocaine hydrochloride (xylocaine, AstraZeneca) mixed with triamcinolone 40 milligrams (Kenacort, Bristol Myers Squip) will be injected in each SIJ.
Retroclavicular approach to the infraclavicular region, the probe will be placed below and perpendicular to the clavicle, in a paramedian sagittal plane, medial to the coracoid process, to obtain a short-axis view of the cords of the brachial plexus and the axillary vessels. The needle will then be inserted in the supraclavicular fossa, approximately 1 cm posteriorly to the clavicle, and advanced in plane and strictly parallel to the ultrasound transducer. After passing the initial blind zone of about 2 cm caused by the acoustic shadow of the clavicle, the needle tip will be constantly seen, until it will be positioned posterior to the axillary artery.
<P>PROBLEM TO BE SOLVED: To obtain a skin beautifying agent and a beauty and health food each containing a collagen peptide derived from fishes, improving the moistness and springiness of the skin by oral administration and effective for preventing and improving roughened skin, crease, or the like, i.e. skin beautifying effect.  <P>SOLUTION: The collagen peptide derived from fishes and having an average molecular weight of 1,000-10,000 is used in combination with vitamin C and vitamin B2 as an active component of the skin beautifying agent. The collagen peptide derived from fishes is preferably produced by the reverse osmosis of an enzymatic decomposition product of a fish skin, fish bone and/or fish scale extract and preferably has a free amino acid content of ≤1.0 mass% in the solid component and an arsenic content of ≤2 ppm. The average molecular weight of the collagen peptide derived from fishes is preferably 1,000-5,000.  <P>COPYRIGHT: (C)2004,JPO&NCIPI
This study is a randomized, controlled trial using a 2-phase data collection. The first phase is the initial assessment for ADHD and includes all patients eligible to be assessed for ADHD as determined by their clinician in the course of usual care. The baseline measurements will be used to compare groups at baseline, and also for longitudinal analyses of medication management. Patients are randomized at this point. Patients in both treatment arms who then receive an ADHD diagnosis and who start medication for ADHD will be eligible for the second phase of the study: three follow-up assessments over six months. Patients who do not have an ADHD diagnosis will not continue in the study, and will be treated by their clinician as usual.
Adult Patients with Psoriatic Arthritis, Plaque Psoriasis, or Behçet's Disease

The recommended initial dosage titration of OTEZLA from Day 1 to Day 5 is shown in Table 1. Following the 5-day titration, the recommended maintenance dosage is 30 mg twice daily taken orally starting on Day 6. This titration is intended to reduce the gastrointestinal symptoms associated with initial therapy.

Pediatric Patients 6 Years of Age and Older and Weighing at Least 20 kg with Moderate to Severe Plaque Psoriasis

The recommended dosage for pediatric patients 6 years of age and older and weighing at least 20 kg with moderate to severe plaque psoriasis is based on body weight. Following the appropriate initial titration schedule shown in Table 2, the recommended maintenance dosage of OTEZLA taken orally is 30 mg twice daily for pediatric patients who weigh at least 50 kg and 20 mg twice daily for pediatric patients who weigh from 20 kg to less than 50 kg. This titration is intended to reduce the gastrointestinal symptoms associated with initial therapy.
A skills-lap course (1 day) followed by opportunity to perform 20 planned surgical procedures of each type (open groin hernia repair and laparoscopic cholecystectomy) under supervision and within 4-8 weeks. Videorecording at start, mid and end and at follow-up before ending first year of training.
FIELD: medicine, biotechnology, genetic therapy. SUBSTANCE: invention relates to vaccine against hepatitis viruses. Invention involves the nucleic acid molecule that comprises the not full genome of fused viruses of hepatitis C and hepatitis B or the not full genome of hepatitis C virus comprising the nucleotide sequence encoding the full core protein of hepatitis C and S-gene protein of hepatitis B, or the not full viral genome of hepatitis C comprising the nucleotide sequence encoding the full core protein of hepatitis C bound operatively with regulatory elements functioning in human cells. Invention describes also pharmaceutical compositions comprising such structures. The advantage of invention involves the development of gene structures that can be effective for protection against viruses of hepatitis B, and/or hepatitis C. EFFECT: enhanced effectiveness of vaccines. 1 4 cl, 3 dwg, 4 ex
The study is a randomized, single-blind trial. Measurements will be obtained before the randomization, after the intervention period of 10 weeks, and at 12 months. Recruitment will begin following institutional review board approval. The patients will participate in the study after signing an informed consent form prior to data collection. Patients will be included if they were 18 years of age or over; had chronic neck pain (i.e. of more than 3 months duration\[19\] ; able to attend a full course of 30 treatments, given three times a week. Cervical lordosis measurements (absolute rotation angle ARA C2-C7 using the angle of intersection of two lines drawn along the posterior vertebral body margins of C2 and C7, respectively) were used as a screen for participants' inclusion. \[20\]\[21\]\[22\] The anterior head translation (AHT) was measured from the posterior superior body of C2 to the vertical line passing through the posterior inferior body of C7. AHT distance had to exceed 25 mm and ARA C2-C7 had to be less than 20° \[20\] for subjects to be included. Participants were excluded if they presented with any of the following: (i) signs or symptoms of systemic pathology and inflammatory joint disease; (ii) prior history of cervical spine trauma and musculoskeletal system surgery, or disorders related to the spine and extremities. An independent person will assign participants at random to a traditional (control) treatment group (55) or to the intervention group (55). A random number generator was used to select numbers from sealed envelopes. Randomization was conducted through permuted blocks of diverse sizes. These blocks were used to generate a sequence of successively numbered, opaque, sealed envelopes that were kept in a locked drawer. The next envelope in the sequence will be opened by the researcher in the presence of the participant.

Both the intervention group and the traditional treatment group will complete a multimodal program of 10 weeks consisting of myofascial release, thoracic spine mobilization and manipulations, and physical pain relief methods. Additionally, the intervention group will receive the denneroll cervical traction orthotic in an attempt to improve the altered sagittal cervical spine alignment (AHT and ARA C2-C7). The first follow up evaluations will be conducted at the end of the 10-weeks (30 sessions) multimodal program while the second follow up was conducted 1 year after finishing the 10-weeks intervention program.

P All the intervention program will be delivered individually by the same physiotherapist, who has received certified training in these manual techniques in order to minimize inter-therapist variation and enhance fidelity.
The present invention provides an interactive physiology monitoring and sharing system to be used in a social media. The present invention comprises a Bluetooth physiological sensor and a server. The Bluetooth physiological sensor is used for sensing and sending a physiological data. The server is connected to the social media and the Bluetooth physiological sensor for receiving the physiological data. An agent is pre-stored in the server. Wherein, when the server receives a user message from the social media, the agent analyzes the user message and the physiological data to generate and send a feedback message to the social media. Through the social media and the agent, users can easily share their health status and receive health advice without wasting medical resources.
Background: Research surrounding the coronavirus disease 2019 (COVID-19) pandemic and its impact on patients who are atopic has mainly focused on adults. After the delta variant showed increased rates of COVID-19 in children, the pediatric population needs to be assessed as well. Objective: The objective was to assess and report outcomes in patients with COVID-19 and with and without certain atopic diseases in our patient cohort at the University of Mississippi Medical Center. Methods: We conducted a retrospective review of patients by using a de-identified data base that allows querying via medical claims codes from the University of Mississippi Medical Center's Research Data Warehouse. We searched for patients who were COVID-19 positive and ages 0-21 years from January 1, 2020, to December 31, 2021. We then divided this population into two cohorts: an atopic population and a non-atopic population. The incidence of hospitalizations, intensive care unit (ICU) admissions, death, length of stay, inhaled corticosteroid prescription history, and the incidence of multi-system inflammatory syndrome in children (MIS-C) outcomes in the two populations were collected. Results: There were 5261 patients ages 0-21 years and with confirmed COVID-19. After exclusion criteria were applied, there were 1420 patients in the atopic cohort and 2525 patients in the non-atopic cohort. There were more hospitalizations and a longer length of stay in the atopic population. Mortality was equivalent in the atopic and non-atopic populations. There were more ICU admissions in the atopic population. There were 101 patients total with the diagnosis of MIS-C, and the incidence of MIS-C was similar in the atopic and non-atopic populations. There were more patients who were atopic on inhaled corticosteroid than were the patients who were non-atopic. Conclusion: This study sought to further elucidate whether asthma, atopic dermatitis, and allergic rhinitis in pediatric patients was associated with severe COVID-19. Our study showed increased hospitalizations, length of stay, and intensive care in the atopic population but similar outcomes in mortality and the development of MIS-C. Future longitudinal prospective studies are needed to assess the long-term effects on patient's atopic disease after COVID-19 infection.
The role of processing bodies (P-bodies) in tumorigenesis and tumor progression is not well understood. Here, we showed that the oncogenes YAP/TAZ promote P-body formation in a series of cancer cell lines. Mechanistically, both transcriptional activation of the P-body-related genes SAMD4A, AJUBA, and WTIP and transcriptional suppression of the tumor suppressor gene PNRC1 are involved in enhancing the effects of YAP/TAZ on P-body formation in colorectal cancer (CRC) cells. By reexpression of PNRC1 or knockdown of P-body core genes (DDX6, DCP1A, and LSM14A), we determined that disruption of P-bodies attenuates cell proliferation, cell migration, and tumor growth induced by overexpression of YAP5SA in CRC. Analysis of a pancancer CRISPR screen database (DepMap) revealed co-dependencies between YAP/TEAD and the P-body core genes and correlations between the mRNA levels of SAMD4A, AJUBA, WTIP, PNRC1, and YAP target genes. Our study suggests that the P-body is a new downstream effector of YAP/TAZ, which implies that reexpression of PNRC1 or disruption of P-bodies is a potential therapeutic strategy for tumors with active YAP.
This study aimed to investigate the impact of physical activity indicators monitored by the POLAR accelerometer on body obesity indicators, metabolic syndrome parameters, and energy metabolism hormones in postmenopausal women. Was included 71 participants from this study program (68.8 ± 4.3 years). We divided participants into LPA and MVPA groups based on their level of moderate to vigorous physical activity per week; Physical activity levels over 7 days were assessed using a POLAR accelerometer, with daily step counts and sedentary time recorded. Measurements included waist circumference, visceral fat volume, body fat percentage, blood pressure, fasting blood glucose, triglyceride levels, HDL cholesterol, and energy metabolism hormone levels (leptin, resistin, adiponectin). The MVPA group displayed lower waist circumference, body fat percentage, abdominal fat, and BMI compared to the LPA group (p < 0.05). A significant negative correlation was observed between daily step count and obesity indicators, including waist circumference (r = -0.301), body fat percentage (r = -0.295), abdominal fat (r = -0.318), and BMI (r = -0.238). Conversely, sedentary time showed a positive correlation with obesity indicators such as waist circumference (r = 0.258), body fat percentage (r = 0.239), and abdominal fat (r = 0.244). Moreover, daily step count exhibited a significant negative correlation with leptin levels (r = -0.245), while sedentary time was positively correlated with the energy metabolic factor leptin (r = 0.279). Waist circumference demonstrated significant positive correlations with triglycerides, blood glucose, adiponectin, resistin, and leptin levels. Postmenopausal women who engage in at least 150 min of MVPA weekly show lower obesity indices. There is a significant correlation between physical activity levels and obesity indicators, which relate to metabolic syndrome and energy metabolism factors. Thus, increased physical activity may help prevent metabolic syndrome and cardiovascular diseases in this population.
PURPOSE:To retrieve easily and quickly pictures, etc. of the same part of the same patient obtained by plural image pickup devices by inputting a retrieval keyword corresponding to retrieval data on a photographed part and the patient name beforehand. CONSTITUTION:Picture signal from an X-ray image pickup device 11, etc., are recorded in a memory device 21 together with retrieval data from an operator's operational board 24 through interfaces I/F16-20 and a selector 23. In terms of display of required picture, data from the picture data is retrieved through operations of the prescribed key and a retrieval keyword corresponding to retrieval data on a photographed part and patient name inputted beforehand, and displayed on a display device 25. Afterward, the picture data by other image pickup devices can be observed in the preset order only by operating the prescribed key on the operational board 24 accordingly. Therefore, pictures, etc. of the same part of the same patient obtained by plural image pickup devices can be retrieved easily at a high speed.
PURPOSE: A cosmetic composition containing extracts of baby brier and Lespedeza cuneata is provided to ensure whitening and antioxidation effects and to obtain a natural functional cosmetic ingredient without skin toxicity. CONSTITUTION: A cosmetic composition for whitening and antioxdation contains 0.001-5% of extracts of baby brier and Lespedeza cuneata. The extract is prepared using a solvent selected from water and anhydrous or hydrous C1-C4 alcohols. The solvent is 70(wt/wt)% hydrous ethanol. The cosmetic composition contains baby brier and Lespedeza cuneata mixed in a weight ratio of 1:3-3:1. The cosmetic composition is manufactured in the form of a skin softener, a lotion, a nutrition cream, a massage cream, a nutrition serum, an essence, or a pack.
BACKGROUND: Infantile myofibromatosis (IM) is a rare disorder characterized by benign tumors in the skin, subcutaneous tissue, muscle, and occasionally viscera. IM can be hereditary due to PDGFRB or NOTCH3 variants. Treatment is mainly conservative or surgical. Combination regimens have been used in case of disseminated disease.
OBSERVATION: We present relapsed disease of IM 11 years after diagnosis in a 2-year-old child initially treated by microscopically complete resection. A new heterozygous c.1687G>A (p.Glu563Lys) mutation in the PDGFRB gene was identified (considered likely pathogenic).
CONCLUSIONS: In association with initial treatment, genetic testing is crucial for tailored clinical practice and follow-up in patients diagnosed with IM.
INTRODUCTION AND HYPOTHESIS: In order to improve the knowledge POP physiopathology and POP repair, a generic biomechanical model of the female pelvic system has been developed. In the literature, no study has currently evaluated apical prolapse repair by posterior sacrospinous ligament fixation using a generic model nor a patient-specific model that personalize the management of POP and predict surgical outcomes based on the patient's pre-operative Magnetic Resonance Imaging. The aim of our study was to analyze the influence of a right and/or left sacrospinous ligament fixation and the distance between the anchorage area and the ischial spine on the pelvic organ mobility using a generic and a patient-specific Finite Element model (FEM) of the female pelvic system during posterior sacrospinous ligament fixation (SSF).
METHODS: Firstly, we used a generic 3D FEM of the female pelvic system previously made by our team that allowed us to simulate the mobility of the pelvic system. To create a patient-specific 3D FEM of the female pelvic system, we used a preoperative dynamic pelvic MRI of a 68 years old woman with a symptomatic stage III apical prolapse and cystocele. With these 2 models, a SSF was simulated. A right and/or left SSF and different distances between the anchorage area and the ischial spine (1 cm, 2 cm and 3 cm.) were compared. Outcomes measures were the pelvic organ displacement using the pubococcygeal line during maximal strain: Ba point for the most posterior and inferior aspect of the bladder base, C point the cervix's or the vaginal apex and Bp point for the anterior aspect of the anorectal junction.
RESULTS: Overall, pelvic organ mobility decreased regardless of surgical technique and model. According to the generic model, C point was displaced by 14.1 mm and 11.5 mm, Ba point by 12.7 mm, and 12 mm and Bp point by 10.6 mm and 9.9 mm after left and bilateral posterior SSF, respectively. C point was displaced by 15.4 mm and 11.6 mm and Ba point by 12.5 mm and 13.1mm when the suture on the sacrospinous ligament was performed at 1 cm and 3 cm from the ischial spine respectively (bilateral posterior SSF configuration). According to the patient-specific model, the displacement of Ba point could not be analyzed because of a significative and asymmetric organ displacement of the bladder. C point was displaced by 4.74 mm and 2.12 mm, and Bp point by 5.30 mm and 3.24 mm after left and bilateral posterior SSF respectively. C point was displaced by 4.80 mm and 4.85 mm and Bp point by 5.35 mm and 5.38 mm when the suture on the left sacrospinous ligament was performed at 1 cm and 3 cm from the ischial spine, respectively.
CONCLUSION: According to the generic model from our study, the apex appeared to be less mobile in bilateral SSF. The anchorage area on the sacrospinous ligament seems to have little effect on the pelvic organ mobilities.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04551859.
The present invention relates to a glucoside compound of catechin, a preparation method thereof and an application thereof. The compound provided by the present invention is dextrogyrate catechin-3-O-glucoside and has a structural formula (I). The compound is obtained by separating from PotentillaviscosaJ. Den and discloses a preparation method. By the experimental verification of medicine effect, the compound has obvious anti-liver damage function and can be used for preparing medicine for curing hepatitis. The present invention has good prospect for the comprehensive development and the use of the potentillaviscosaJ. Den as a wild resource and provides a possibility for preparing new medicine for curing the hepatitis.
The invention discloses an onychomycosis ointment and a preparation method thereof. The onychomycosis ointment consists of salicylic acid, benzylacid and vaseline and the preparation method is as follows: mixing salicylic acid and benzylacid in powder forms evenly; mixing with the matrix vaseline to obtain the ointment. The ointment can be smeared on the onychomycosis, and then the onychomycosis can be covered by a woundplast, thus being a simple treatment. The pharmacological actions of the invention are as follows: forming a protective film on the fingernail surface; permeating and softening the disease nails with effective ingredients; killing microorganisms of various pathogenic fungi. A medicine-use observation towards 200 onychonycosis patients caused by various reasons proves that by cleaning the disease nails, smearing the ointment for three to four times, changing the dressing every three days, 10 to 15 days later, 200 onychomycosis patients all recover. The test proves that the ointment has non-toxicity, no allergy effect towards the skin, can soften the disease nails rapidly; the ointment further has the advantages of good sterilization effect and short course of treatment.
Kit for the Preparation of Technetium Tc99m Sestamibi for Injection is supplied as a 5 mL vial in a kit of twenty (20) vials (NDC # 11994-003-20), sterile and non-pyrogenic.

The patient dose should be measured by a suitable radioactivity calibration system immediately prior to patient administration. Radiochemical purity should be checked prior to patient administration.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.

Store at 15-25°C (59-77°F) before and after reconstitution.

Prior to lyophilization the pH is between 5.3 and 5.9. The contents of the vial are lyophilized and stored under nitrogen. Store at 15-25°C (59-77°F) before and after reconstitution. Technetium Tc99m Sestamibi contains no preservatives. Included in each twenty (20) vial kit is one (1) package insert, twenty four (24) vial shield labels and twenty four (24) radiation warning labels.

This reagent kit is approved for distribution to persons licensed pursuant to the Code of Massachusetts Regulations 105 CMR 120.500 for the uses listed in 105 CMR 120.547 or 120.552, or under equivalent regulations of the U.S. Nuclear Regulatory Commission, Agreement States or Licensing States.